Shop Online｜LA EXO｜MOMO
Company Profile
Development History
Management Team
Service
ExoGiov® Inspection
ExoGiov® Efficacy
shop online
What Is Exosome
GMP Laboratory & Facilities
International CertificationCell Manufacturing Facilities
Clinical Trial Programs
Major Application Areas
Bio-Pulsed Platform
Meet the unmet medical needs
Patented Bio-Pulsed Technology Platform
Our Bio-Pulsed technology modifies the cellular culture microenvironment and precisely controls biochemical stimulation conditions—known as “biochemical pulses”—to induce cells to secrete targeted exosomes with specific biological functions.
Unlike conventional exosomes, which are without functional induction, AM Biotech’s proprietary Bio-Pulsed technology precisely regulates the miRNA cargo and functional biological signals carried by exosomes according to specific application needs, providing more clearly defined mechanisms of action and enhanced biological activity. Through miRNA profiling and functional validation, their active components and functional characteristics can be further characterized, establishing an exosome platform built on the concept of functionally defined APIs (Active Pharmaceutical Ingredients) and expanding its potential for pharmaceutical and regenerative medicine applications.
Growth Milestones
Patents Granted in 22 Countries, Strengthening Global Technology Barriers
AM Biotech’s proprietary Bio-Pulsed Exosome Induction Technology has been patented in 22 countries, including Taiwan, China, Japan, South Korea, the United States, and the European Union (15+2 participating countries). These patents demonstrate the originality of the technology and establish strong barriers to entry, providing a solid foundation for its clinical application and commercialization.
Extensive International Academic Publications Establishing a Foundation for Clinical Applications
AM Biotech consistently publishes cutting-edge exosome research in international journals, bridging fundamental science with clinical validation. Supported by robust data, this expanding body of work reinforces the credibility of our platform while highlighting the depth, versatility, and academic value of our applications.
Strategic Investment Partnerships Accelerating Medical Market Expansion
AM Biotech has secured strategic investments from Qisda Group and Chang Hwa Bank Venture Capital. Qisda’s extensive healthcare ecosystem and market network will significantly enhance AM Biotech’s translation capabilities and commercial capabilities. These partnerships will accelerate the development of an integrated healthcare ecosystem —from R&D to market deployment— while advancing the clinical application of AM Biotech’s exosome technology.
International Quality Recognition for Outstanding Efficacy and Trusted Safety
ExoGiov® Bio-Pulsed Exosomes, received an INCI designation in 2021. In 2024, the ingredient was selected by The Estée Lauder Companies as one of the world’s Top 5 innovations for cross-generational beauty, followed by Halal Certification in 2026. These international recognitions demonstrate its high standards of quality, efficacy, and safety, supporting its compliant application and commercialization across global markets.
National Recognition Reinforcing Leadership in Exosome Technology
AM Biotech received the 21st National Innovation Award for its “Cross-Generational Functionally Induced Bio-Pulsed Exosome Application Technology Platform.” This recognition highlights the depth of AM Biotech’s exosome R&D capabilities and reinforces its leadership in regenerative medicine and cosmetics, marking a significant milestone in the clinical translation and commercialization of its technology.
ExoGiov® Bio-Pulsed Exosomes
Halal Certified
A commitment to purity, safety, and traceability
Leading the Global Expansion of Exosome Technology
